These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12145649)

  • 41. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 42. Strengthening the supply of routinely recommended vaccines in the United States: a perspective from the American Medical Association.
    Tan L;
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S121-4. PubMed ID: 16447133
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunization supply chains: Why they matter and how they are changing.
    Rao R; Schreiber B; Lee BY
    Vaccine; 2017 Apr; 35(17):2103-2104. PubMed ID: 28364914
    [No Abstract]   [Full Text] [Related]  

  • 44. Is our vaccine system at risk for a future financial "meltdown?".
    Berman S
    Pediatrics; 2008 Dec; 122(6):1372-3. PubMed ID: 19047260
    [No Abstract]   [Full Text] [Related]  

  • 45. Overcoming economic barriers to the optimal use of vaccines.
    Lieu TA; McGuire TG; Hinman AR
    Health Aff (Millwood); 2005; 24(3):666-79. PubMed ID: 15886158
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reporting adverse vaccine events.
    O'Rourke K
    J Am Vet Med Assoc; 2003 Sep; 223(6):753-4. PubMed ID: 14507079
    [No Abstract]   [Full Text] [Related]  

  • 47. [Vaccines. III. Vaccines of cellular fractions].
    Bojalil LF
    Gac Med Mex; 1976 Apr; 111(4):263-7. PubMed ID: 939368
    [No Abstract]   [Full Text] [Related]  

  • 48. Preventing vaccine-preventable diseases in low-resource communities.
    Rodewald LE; Markowitz LE
    Arch Pediatr Adolesc Med; 2009 May; 163(5):487-8. PubMed ID: 19414699
    [No Abstract]   [Full Text] [Related]  

  • 49. Triage in the nation's medicine cabinet: the puzzling scarcity of vaccines and other drugs.
    Noah L
    S C Law Rev; 2002; 54(2):371-403. PubMed ID: 15156891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Financing immunizations in the United States.
    Hinman AR; Orenstein WA; Rodewald L
    Clin Infect Dis; 2004 May; 38(10):1440-6. PubMed ID: 15156483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Battle of the mind.
    Check E
    Nature; 2003 Mar; 422(6930):370-2. PubMed ID: 12660749
    [No Abstract]   [Full Text] [Related]  

  • 52. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Standards for child and adolescent immunization practices. National Vaccine Advisory Committee.
    National Vaccine Advisory Committee
    Pediatrics; 2003 Oct; 112(4):958-63. PubMed ID: 14523192
    [No Abstract]   [Full Text] [Related]  

  • 54. The U.S. vaccine supply.
    Schwartz HK
    N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15762001
    [No Abstract]   [Full Text] [Related]  

  • 55. Infant immunizations don't increase risk of certain illnesses, panel says.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 Mar; 13(5):1-2, 5. PubMed ID: 12440405
    [No Abstract]   [Full Text] [Related]  

  • 56. Regulation of vaccines: strengthening the science base.
    Milstien JB
    J Public Health Policy; 2004; 25(2):173-89; discussion 190-6. PubMed ID: 15255384
    [TBL] [Abstract][Full Text] [Related]  

  • 57. When information must be revealed.
    Ventura MJ
    RN; 1999 Feb; 62(2):61-4. PubMed ID: 10086020
    [No Abstract]   [Full Text] [Related]  

  • 58. Immunity for immunizations: tort liability, biodefense, and Bioshield II.
    Mayer L
    Stanford Law Rev; 2007 Apr; 59(6):1753-90. PubMed ID: 17593591
    [No Abstract]   [Full Text] [Related]  

  • 59. Monitoring the impact of vaccines postlicensure: new challenges, new opportunities.
    Schuchat A; Bell BP
    Expert Rev Vaccines; 2008 May; 7(4):437-56. PubMed ID: 18444891
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of globalization on vaccine development and availability.
    Milstien JB; Kaddar M; Kieny MP
    Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.